Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel...
Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel for its peginesatide treatment of anemia in dialysis patients. Cowen believes the drug can capture $250M in U.S. sales by 2016, and Raymond James suspects AFFY can take market share if it prices its drug lower than Amgen's (AMGN +1%) Epogen.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Jun 3, 2013)
at CNBC.com (May 31, 2013)
at MarketWatch.com (Apr 2, 2013)
at MarketWatch.com (Mar 19, 2013)
at CNBC.com (Mar 19, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs